Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026)

Neumora Therapeutics' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 21.38% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$222.4 million (up 13.82% YoY), while the FY2025 annual figure was -$236.9 million, up 2.81% from the prior year.
• Net Income towards Common Stockholders was -$53.5 million for Q1 2026 at Neumora Therapeutics, up from -$59.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$28.4 million in Q4 2022 to a low of -$108.5 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$55.2 million across 5 years, with a median of -$53.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 281.47% in 2023, then jumped 45.77% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$28.4 million in 2022, then slumped by 281.47% to -$108.5 million in 2023, then surged by 45.77% to -$58.8 million in 2024, then declined by 1.07% to -$59.4 million in 2025, then rose by 10.08% to -$53.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$53.5 million (Q1 2026), -$59.4 million (Q4 2025), and -$56.8 million (Q3 2025), per Business Quant data.